Literature DB >> 8533197

Infrequent involvement of mutations on neurofibromatosis type 1, H-ras, K-ras and N-ras in urothelial tumors.

T Uchida1, C Wada, H Ishida, S Egawa, T Ao, E Yokoyama, K Koshiba.   

Abstract

The neurofibromatosis type 1 (NF1) gene is considered a tumor-suppressor gene whose product acts upstream of ras. The ras gene is an oncogene very commonly detected in human cancers and consists of three families, H-ras, K-ras and N-ras. These genes are converted to active oncogenes by point mutations in codon 12, 13, or 61. Examination was made of the mutations of these genes in 39 urothelial malignant tumors (31 bladder cancer, 6 renal pelvic tumor, and 2 ureter tumors) using polymerase chain reaction single-stranded conformation polymorphism and direct sequencing methods. Three of 39 (7.7%) cases showed mobility shifts in the ras family gene but no point mutations in NF1 and N-ras genes could be detected. Mutations were found in 1 case in H-ras at codon 13 (GGT-GTT/GGT) and K-ras at codon 12 in 2 cases (GGT-GCT/GGT, GGT-GTT/GGT). All 3 cases had progressed far beyond grade 2 and stage pT2. It follows from the above that NF1 and ras gene mutations are infrequent in the pathogenesis of urothelial tumors.

Entities:  

Mesh:

Year:  1995        PMID: 8533197     DOI: 10.1159/000282753

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  8 in total

Review 1.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro.

Authors:  V Aaltonen; P J Boström; K O Söderström; O Hirvonen; J Tuukkanen; M Nurmi; M Laato; J Peltonen
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

3.  c-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas.

Authors:  Keiji Shimada; Mitsutoshi Nakamura; Eiwa Ishida; Tomonori Higuchi; Motoyoshi Tanaka; Ichiro Ota; Noboru Konishi
Journal:  Am J Pathol       Date:  2007-08-09       Impact factor: 4.307

4.  The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer.

Authors:  Slah Ouerhani; Karim Bougatef; Ismail Soltani; Amel Ben Ammar Elgaaied; Salem Abbes; Samia Menif
Journal:  Mol Biol Rep       Date:  2013-05-03       Impact factor: 2.316

5.  Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis.

Authors:  I Ahmad; R Patel; Y Liu; L B Singh; M M Taketo; X-R Wu; H Y Leung; O J Sansom
Journal:  Cell Death Dis       Date:  2011-03-03       Impact factor: 8.469

6.  K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder.

Authors:  Imran Ahmad; Lukram Babloo Singh; Mona Foth; Carol-Ann Morris; Makoto Mark Taketo; Xue-Ru Wu; Hing Y Leung; Owen J Sansom; Tomoko Iwata
Journal:  Dis Model Mech       Date:  2011-04-18       Impact factor: 5.758

7.  Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia.

Authors:  Xiaoping Yang; Francisco G La Rosa; Elizabeth Erin Genova; Kendra Huber; Jerome Schaack; James Degregori; Natalie J Serkova; Yuan Li; Lih-Jen Su; Elizabeth Kessler; Thomas W Flaig
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

8.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.